These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 22743654)

  • 1. ALK alterations in adult renal cell carcinoma: frequency, clinicopathologic features and outcome in a large series of consecutively treated patients.
    Sukov WR; Hodge JC; Lohse CM; Akre MK; Leibovich BC; Thompson RH; Cheville JC
    Mod Pathol; 2012 Nov; 25(11):1516-25. PubMed ID: 22743654
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Genetic analysis and clinicopathological features of ALK-rearranged renal cell carcinoma in a large series of resected Chinese renal cell carcinoma patients and literature review.
    Yu W; Wang Y; Jiang Y; Zhang W; Li Y
    Histopathology; 2017 Jul; 71(1):53-62. PubMed ID: 28199742
    [TBL] [Abstract][Full Text] [Related]  

  • 3. ALK-Rearranged Renal Cell Carcinoma: A Multi-Institutional Study of 9 Cases With Expanding the Morphologic and Molecular Genetic Spectrum.
    Zhao M; Yin X; Yang X; Gan H; Chen N; Duan G; Bai Y; Teng X; Xu J; Fang R; Wang S; Zhong S; Wang X; Teng L
    Mod Pathol; 2024 Aug; 37(8):100536. PubMed ID: 38852815
    [TBL] [Abstract][Full Text] [Related]  

  • 4. TFE3 rearrangements in adult renal cell carcinoma: clinical and pathologic features with outcome in a large series of consecutively treated patients.
    Sukov WR; Hodge JC; Lohse CM; Leibovich BC; Thompson RH; Pearce KE; Wiktor AE; Cheville JC
    Am J Surg Pathol; 2012 May; 36(5):663-70. PubMed ID: 22498819
    [TBL] [Abstract][Full Text] [Related]  

  • 5. ALK rearrangement in TFE3-positive renal cell carcinoma: Alternative diagnostic option to exclude Xp11.2 translocation carcinoma.
    Zhu Y; Liu N; Guo W; Pu X; Guo H; Gan W; Li D
    Pathol Res Pract; 2020 Dec; 216(12):153286. PubMed ID: 33197836
    [TBL] [Abstract][Full Text] [Related]  

  • 6. ALK gene copy number gain and its clinical significance in hepatocellular carcinoma.
    Jia SW; Fu S; Wang F; Shao Q; Huang HB; Shao JY
    World J Gastroenterol; 2014 Jan; 20(1):183-92. PubMed ID: 24415871
    [TBL] [Abstract][Full Text] [Related]  

  • 7.
    Wangsiricharoen S; Zhong M; Ranganathan S; Matoso A; Argani P
    Int J Surg Pathol; 2021 Oct; 29(7):808-814. PubMed ID: 33729862
    [TBL] [Abstract][Full Text] [Related]  

  • 8. ALK rearrangements-associated renal cell carcinoma (RCC) with unique pathological features in an adult.
    Jeanneau M; Gregoire V; Desplechain C; Escande F; Tica DP; Aubert S; Leroy X
    Pathol Res Pract; 2016 Nov; 212(11):1064-1066. PubMed ID: 27554841
    [TBL] [Abstract][Full Text] [Related]  

  • 9. ALK rearranged renal cell carcinoma (ALK-RCC): a multi-institutional study of twelve cases with identification of novel partner genes CLIP1, KIF5B and KIAA1217.
    Kuroda N; Trpkov K; Gao Y; Tretiakova M; Liu YJ; Ulamec M; Takeuchi K; Agaimy A; Przybycin C; Magi-Galluzzi C; Fushimi S; Kojima F; Sibony M; Hang JF; Pan CC; Yilmaz A; Siadat F; Sugawara E; Just PA; Ptakova N; Hes O
    Mod Pathol; 2020 Dec; 33(12):2564-2579. PubMed ID: 32467651
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Higher expression of topoisomerase II alpha is an independent marker of increased risk of cancer-specific death in patients with clear cell renal cell carcinoma.
    Parker AS; Eckel-Passow JE; Serie D; Hilton T; Parasramka M; Joseph RW; Wu KJ; Cheville JC; Leibovich BC
    Eur Urol; 2014 Nov; 66(5):929-35. PubMed ID: 24388441
    [TBL] [Abstract][Full Text] [Related]  

  • 11. VCL-ALK renal cell carcinoma in children with sickle-cell trait: the eighth sickle-cell nephropathy?
    Smith NE; Deyrup AT; Mariño-Enriquez A; Fletcher JA; Bridge JA; Illei PB; Netto GJ; Argani P
    Am J Surg Pathol; 2014 Jun; 38(6):858-63. PubMed ID: 24698962
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Identification of anaplastic lymphoma kinase fusions in renal cancer: large-scale immunohistochemical screening by the intercalated antibody-enhanced polymer method.
    Sugawara E; Togashi Y; Kuroda N; Sakata S; Hatano S; Asaka R; Yuasa T; Yonese J; Kitagawa M; Mano H; Ishikawa Y; Takeuchi K
    Cancer; 2012 Sep; 118(18):4427-36. PubMed ID: 22252991
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Correlations between the percentage of tumor cells showing an anaplastic lymphoma kinase (ALK) gene rearrangement, ALK signal copy number, and response to crizotinib therapy in ALK fluorescence in situ hybridization-positive nonsmall cell lung cancer.
    Camidge DR; Theodoro M; Maxson DA; Skokan M; O'Brien T; Lu X; Doebele RC; Barón AE; Varella-Garcia M
    Cancer; 2012 Sep; 118(18):4486-94. PubMed ID: 22282074
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Native and rearranged ALK copy number and rearranged cell count in non-small cell lung cancer: implications for ALK inhibitor therapy.
    Camidge DR; Skokan M; Kiatsimkul P; Helfrich B; Lu X; Barón AE; Schulte N; Maxson D; Aisner DL; Franklin WA; Doebele RC; Varella-Garcia M
    Cancer; 2013 Nov; 119(22):3968-75. PubMed ID: 24022839
    [TBL] [Abstract][Full Text] [Related]  

  • 15. ALK-TPM3 rearrangement in adult renal cell carcinoma: a case report and literature review.
    Yang J; Dong L; Du H; Li XB; Liang YX; Liu GR
    Diagn Pathol; 2019 Oct; 14(1):112. PubMed ID: 31627758
    [TBL] [Abstract][Full Text] [Related]  

  • 16. ALK-rearranged renal cell carcinoma (ALK-RCC): Evaluation of histomorphological and immunohistochemical features by analysis of 276 renal cell carcinoma cases in Turkey.
    Doğan K; Onder E
    Pathol Res Pract; 2024 Jan; 253():154951. PubMed ID: 38039739
    [TBL] [Abstract][Full Text] [Related]  

  • 17. ALK-rearranged renal cell carcinomas in Polish population.
    Gorczynski A; Czapiewski P; Korwat A; Budynko L; Prelowska M; Okon K; Biernat W
    Pathol Res Pract; 2019 Dec; 215(12):152669. PubMed ID: 31677810
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Histologic and cytomorphologic features of ALK-rearranged lung adenocarcinomas.
    Nishino M; Klepeis VE; Yeap BY; Bergethon K; Morales-Oyarvide V; Dias-Santagata D; Yagi Y; Mark EJ; Iafrate AJ; Mino-Kenudson M
    Mod Pathol; 2012 Nov; 25(11):1462-72. PubMed ID: 22743652
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Renal cell carcinoma with novel VCL-ALK fusion: new representative of ALK-associated tumor spectrum.
    Debelenko LV; Raimondi SC; Daw N; Shivakumar BR; Huang D; Nelson M; Bridge JA
    Mod Pathol; 2011 Mar; 24(3):430-42. PubMed ID: 21076462
    [TBL] [Abstract][Full Text] [Related]  

  • 20. High Novel Oncogene with Kinase-Domain (NOK) Gene Expression is Associated with the Progression of Renal Cell Carcinoma.
    Cao Q; Chen M; Li Z; Huang W; Jin Y; Ye X; Tong M
    Clin Lab; 2016; 62(1-2):179-86. PubMed ID: 27012048
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.